Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis (65%), asthma (20%), and CRSwNP (10%) as core indications; each faces varying competitive pressures. Revenue projections for ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果当前正在显示可能无法访问的结果。
隐藏无法访问的结果